Spots Global Cancer Trial Database for advanced hepatocellular carcinoma
Every month we try and update this database with for advanced hepatocellular carcinoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Immunotherapy With Nivolumab in Combination With Lenvatinib for Advanced Stage Hepatocellular Carcinoma | NCT03841201 | Advanced Hepato... | Lenvatinib Nivolumab | 18 Years - | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | |
| Study of ARQ 197 in Hepatocellular Carcinoma (HCC) | NCT01656265 | Advanced Hepato... | ARQ 197 | 20 Years - | Kyowa Kirin Co., Ltd. | |
| Organ-specific Responses to Atezolizumab Plus Bevacizumab in Advanced HCC | NCT04862949 | Advanced Hepato... | Atezolizumab pl... | 19 Years - | CHA University | |
| Immunotherapy Using Pluripotent Killer-Programmed Cell Death 1 (PIK-PD-1) Cells for the Treatment of Advanced Hepatocellular Carcinoma | NCT02632006 | Advanced Hepato... | PIK-PD-1 cells DC-PMAT | 20 Years - 70 Years | Second Military Medical University | |
| Study of Apatinib Combined With TACE in Advance Hepatocellular Carcinoma | NCT03398122 | Hepatocellular ... | TACE Apatinib | 18 Years - 70 Years | Tianjin Medical University Cancer Institute and Hospital | |
| SBRT Plus Lenvatinib and TACE for Advanced Primary HCC: A Phase 3 Trial (SEARCH) | NCT05718232 | Advanced Hepato... | Lenvatinib TACE SBRT | 18 Years - 75 Years | Sun Yat-sen University | |
| Study of Apatinib in Advanced Hepatocellular Carcinoma(HCC) | NCT03046979 | Hepatocellular ... | Apatinib | 18 Years - 75 Years | Tianjin Medical University Cancer Institute and Hospital | |
| ATEZOLIZUMAB - BEVACIZUMAB in the Treatment Hepatocellular Carcinoma Inoperable or | NCT04730388 | Advanced Hepato... | 18 Years - 99 Years | University Hospital, Brest | ||
| To Evaluate the Safety, Tolerability and Preliminary Efficacy of EU307 | NCT05783570 | Advanced Hepato... | EU307 CAR-T Cel... | 19 Years - | Eutilex | |
| A Clinical Research Study to Determine Whether PD 0332991 May Be Effective in Treating Patients With Liver Cancer | NCT01356628 | Advanced Hepato... HCC Liver Cancer | PD-0332991 | 18 Years - | Thomas Jefferson University | |
| Comparing Efficacy of Sorafenib Versus Sorafenib in Combination With Low-dose FP in Patients With Advanced HCC | NCT01214343 | Advanced Hepato... Carcinoma Carcinoma, Hepa... Liver Neoplasms Neoplasms | Sorafenib with ... Sorafenib | 20 Years - | Ministry of Health, Labour and Welfare, Japan | |
| Cabozantinib and Pembrolizumab for the First-Line Treatment of Advanced Liver Cancer | NCT04442581 | Advanced Hepato... BCLC Stage B He... BCLC Stage C He... | Cabozantinib S-... Pembrolizumab | 18 Years - | University of Washington | |
| A Trial of Hepatic Arterial Infusion Combined With Apatinib and Camrelizumab for C-staged Hepatocellular Carcinoma in BCLC Classification | NCT04191889 | C-staged Hepato... | Hepatic Arteria... | 18 Years - 70 Years | Sun Yat-sen University | |
| Pembrolizumab (Keytruda) in Advanced Hepatocellular Carcinoma | NCT02658019 | Hepatocellular ... | Pembrolizumab | 18 Years - | University of Miami | |
| Camrelizumab Utilization on Patients With Advanced Liver Cancer | NCT04487704 | Advanced Hepato... | camrelizumab | 18 Years - | First Affiliated Hospital Xi'an Jiaotong University | |
| 68Ga PSMA PET Imaging for the Treatment of Advanced Liver Cancer | NCT05176223 | Advanced Hepato... Stage III Hepat... Stage IV Hepato... Unresectable He... | Computed Tomogr... Gallium Ga 68 G... Positron Emissi... | 18 Years - | Mayo Clinic | |
| A Study of Cadonilimab Combined With Regorafenib in Patients With Advanced HCC | NCT05773105 | Advanced Hepato... | Cadonilimab+reg... | 18 Years - 75 Years | Sun Yat-sen University | |
| Cabozantinib and Pembrolizumab for the First-Line Treatment of Advanced Liver Cancer | NCT04442581 | Advanced Hepato... BCLC Stage B He... BCLC Stage C He... | Cabozantinib S-... Pembrolizumab | 18 Years - | University of Washington | |
| Temsirolimus as Second-line Therapy in HCC | NCT01567930 | Unresectable or... | Temsirolimus | 18 Years - | University of Tennessee Cancer Institute | |
| Phase 2 Study of TAC-101 Combined With Transcatheter Arterial Chemoembolization (TACE) Versus TACE Alone in Japanese Patients With Advanced Hepatocellular Carcinoma | NCT00667628 | Advanced Hepato... | TAC-101 Placebo | 20 Years - | Taiho Oncology, Inc. | |
| Efficacy and Safety of Sorafenib in Previously Treated Advanced Hepatocellular Carcinoma: SOPT Study | NCT05117957 | Advanced Hepato... | Sorafenib | 20 Years - | National Cancer Center, Korea | |
| Oral Chemotherapy Versus Supportive Therapy In The Treatment Of Unresectable Hepatocellular Carcinoma | NCT01438450 | Hepatocellular ... | Oral Supportive | 12 Years - 70 Years | All India Institute of Medical Sciences, New Delhi | |
| Pembrolizumab (Keytruda) in Advanced Hepatocellular Carcinoma | NCT02658019 | Hepatocellular ... | Pembrolizumab | 18 Years - | University of Miami | |
| Evaluation of the Efficacy of Long-acting Release Octreotide in Patients With Advanced Hepatocellular Carcinoma | NCT00241020 | Advanced Hepato... | Octreotide | 18 Years - | Novartis | |
| Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV | NCT04514484 | Advanced Differ... Advanced Head a... Advanced Hepato... Advanced Kaposi... Advanced Lung N... Advanced Lung S... Advanced Malign... Advanced Melano... Advanced Ovaria... Advanced Prosta... Advanced Renal ... Advanced Thyroi... Advanced Triple... Advanced Urothe... Anatomic Stage ... Anatomic Stage ... Castration-Resi... Clinical Stage ... Clinical Stage ... HIV Infection Metastatic Diff... Metastatic Head... Metastatic Hepa... Metastatic Kapo... Metastatic Lung... Metastatic Lung... Metastatic Mali... Metastatic Mela... Metastatic Ovar... Metastatic Pros... Metastatic Rena... Metastatic Thyr... Metastatic Trip... Metastatic Urot... Recurrent Diffe... Recurrent Head ... Recurrent Hepat... Recurrent Kapos... Recurrent Lung ... Recurrent Lung ... Recurrent Malig... Recurrent Melan... Recurrent Ovari... Recurrent Prost... Recurrent Renal... Recurrent Thyro... Recurrent Tripl... Recurrent Uroth... Refractory Diff... Stage III Diffe... Stage III Hepat... Stage III Lung ... Stage III Ovari... Stage III Prost... Stage III Renal... Stage III Thyro... Stage IV Differ... Stage IV Hepato... Stage IV Lung C... Stage IV Ovaria... Stage IV Prosta... Stage IV Renal ... Stage IV Thyroi... | Biospecimen Col... Cabozantinib S-... Computed Tomogr... Magnetic Resona... Nivolumab | 18 Years - | National Cancer Institute (NCI) | |
| Adebrelimab, Camrelizumab Plus Apatinib as First-line Therapy in Patients With Advanced Hepatocellular Carcinoma | NCT05924997 | Advanced Hepato... | adebrelimab, ca... | 18 Years - | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | |
| Everolimus and Pasireotide (SOM230) in Patients With Advanced or Metastatic Hepatocellular Carcinoma | NCT01488487 | Advanced Adult ... | Everolimus Pasireotide | 18 Years - | UNC Lineberger Comprehensive Cancer Center | |
| Phase III RCT of Radiotherapy Plus Toripalimab Versus Sorafenib in Advanced Hepatocellular Carcinoma With PVTT | NCT04709380 | Radiotherapy Toripalimab Sorafenib Advanced Hepato... | Radiotherapy pl... Sorafenib | 18 Years - 80 Years | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | |
| Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax | NCT05092373 | Advanced Breast... Advanced Endome... Advanced Fallop... Advanced Hepato... Advanced Malign... Advanced Malign... Advanced Malign... Advanced Ovaria... Advanced Primar... Advanced Renal ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Malignant Abdom... Malignant Solid... Metastatic Brea... Metastatic Endo... Metastatic Fall... Metastatic Hepa... Metastatic Mali... Metastatic Mali... Metastatic Mali... Metastatic Ovar... Metastatic Prim... Metastatic Rena... Prognostic Stag... Prognostic Stag... Prognostic Stag... Prognostic Stag... Prognostic Stag... Stage III Fallo... Stage III Hepat... Stage III Ovari... Stage III Prima... Stage III Renal... Stage III Uteri... Stage IIIA Fall... Stage IIIA Hepa... Stage IIIA Ovar... Stage IIIA Prim... Stage IIIA Uter... Stage IIIA1 Fal... Stage IIIA1 Ova... Stage IIIA2 Fal... Stage IIIA2 Ova... Stage IIIB Fall... Stage IIIB Hepa... Stage IIIB Ovar... Stage IIIB Prim... Stage IIIB Uter... Stage IIIC Fall... Stage IIIC Ovar... Stage IIIC Prim... Stage IIIC Uter... Stage IIIC1 Ute... Stage IIIC2 Ute... Stage IV Fallop... Stage IV Hepato... Stage IV Ovaria... Stage IV Primar... Stage IV Renal ... Stage IV Uterin... Stage IVA Fallo... Stage IVA Hepat... Stage IVA Ovari... Stage IVA Prima... Stage IVA Uteri... Stage IVB Fallo... Stage IVB Hepat... Stage IVB Ovari... Stage IVB Prima... Stage IVB Uteri... | Atezolizumab Cabozantinib S-... Nab-paclitaxel Tumor Treating ... | 18 Years - | M.D. Anderson Cancer Center | |
| Durvalumab for Advanced Hepatocellular Carcinoma in Patients With Active Chronic Hepatitis B Virus Infection | NCT04294498 | Advanced Hepato... | Durvalumab | 20 Years - | National Taiwan University Hospital | |
| Efficacy and Safety of IBI310 Combined With Sintilimab in Patients With Advanced Hepatocellular Carcinoma | NCT04401813 | Advanced Hepato... | IBI308 200mg | 18 Years - 75 Years | Innovent Biologics (Suzhou) Co. Ltd. | |
| Safety Study of Foretinib (GSK1363089) in Adults With Liver Cancer | NCT00920192 | Carcinoma, Hepa... | Foretinib | 18 Years - | GlaxoSmithKline | |
| Regorafenib Plus Tislelizumab as First-line Systemic Therapy for Patients With Advanced Hepatocellular Carcinoma | NCT04183088 | Advanced Hepato... | Tislelizumab+re... | 20 Years - | National Taiwan University Hospital | |
| Study of Apatinib in Advanced Hepatocellular Carcinoma(HCC) | NCT03046979 | Hepatocellular ... | Apatinib | 18 Years - 75 Years | Tianjin Medical University Cancer Institute and Hospital | |
| BO-112 and Pembrolizumab for the Treatment of PD-1/PD-L1 Refractory Liver Cancer | NCT04777708 | Advanced Hepato... BCLC Stage B He... BCLC Stage C He... Refractory Hepa... | Nanoplexed Poly... Pembrolizumab | 18 Years - | Jonsson Comprehensive Cancer Center | |
| TACE With Lenvatinib Versus Lenvatinib Alone in in First-line Treatment of Advanced HCC | NCT03905967 | Advanced Hepato... | TACE Lenvatinib | 18 Years - 75 Years | Sun Yat-sen University | |
| YIV-906 (Formerly PHY906/KD018) With Sorafenib in HBV(+) Hepatocellular Carcinoma (HCC) | NCT04000737 | Advanced Hepato... | YIV-906+Sorafen... Placebo+Sorafen... | 18 Years - | Yiviva Inc. | |
| Phase III RCT of Radiotherapy Plus Toripalimab Versus Sorafenib in Advanced Hepatocellular Carcinoma With PVTT | NCT04709380 | Radiotherapy Toripalimab Sorafenib Advanced Hepato... | Radiotherapy pl... Sorafenib | 18 Years - 80 Years | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | |
| XIAP Antisense AEG35156 in Combination With Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC) | NCT00882869 | Advanced Hepato... | AEG35156 antise... Sorafenib | 18 Years - | Aegera Therapeutics | |
| A Trial of Hepatic Arterial Infusion Combined With Apatinib and Camrelizumab for C-staged Hepatocellular Carcinoma in BCLC Classification | NCT04191889 | C-staged Hepato... | Hepatic Arteria... | 18 Years - 70 Years | Sun Yat-sen University | |
| Efficacy and Safety of SBRT Combined With Atezolizumab Plus Bevacizumab vs Atezolizumab Plus Bevacizumab in Treating Unresectable Advance Hepatocellular Carcinoma. | NCT06244446 | Advanced Hepato... | No intervention | 18 Years - 70 Years | Institute of Liver and Biliary Sciences, India | |
| Immunotherapy With Nivolumab in Combination With Lenvatinib for Advanced Stage Hepatocellular Carcinoma | NCT03841201 | Advanced Hepato... | Lenvatinib Nivolumab | 18 Years - | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | |
| A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With FOLFOX4 in Subjects With Advanced HCC Who Have Never Received Prior Systemic Treatment. | NCT03605706 | Advanced Hepato... | SHR-1210 FOLFOX4 Placebo | 18 Years - | Jiangsu HengRui Medicine Co., Ltd. | |
| Efficacy and Safety of Sorafenib in Previously Treated Advanced Hepatocellular Carcinoma: SOPT Study | NCT05117957 | Advanced Hepato... | Sorafenib | 20 Years - | National Cancer Center, Korea | |
| A Phase I, Open Label, Non Randomized, Multicenter, Dose Escalation Clinical Study to Investigate Safety and Tolerability of OPB(Otsuka Pharmaceutical Biwa)-111077 in Subjects With Advanced HCC(Hepatocellular Carcinoma) | NCT01942083 | Advanced Hepato... | OPB-111077 | 20 Years - 75 Years | Korea Otsuka Pharmaceutical Co., Ltd. | |
| Study of GPC-3 CAR-T Cells in Treating With Hepatocellular Carcinoma | NCT05620706 | Advanced Hepato... | GPC3 CAR-T cell... | 40 Years - 70 Years | Shenzhen University General Hospital | |
| Safety and Efficacy of Bifidobacterium Therapy in Patients With Advanced Liver Cancer Receiving Immunotherapy | NCT05620004 | Advanced Hepato... | Bifidobacterium... | 18 Years - 65 Years | Sun Yat-sen University | |
| Clinical Study of TQB2223 Injection Combined With AK105 Injection in the Treatment of Advanced Hepatocellular Carcinoma. | NCT06320080 | Advanced Hepato... | TQB2223 injecti... Penpulimab Inje... | 18 Years - 75 Years | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | |
| A Safety and Efficacy Study of Multiple Tyrosine Kinase Inhibitor Drug (ETN101) in Advanced Hepatocellular Carcinoma | NCT06326502 | Hepatocellular ... Advanced Hepato... Liver Cancer | ETN101 | 19 Years - 65 Years | Etnova Therapeutics Corp. | |
| Immunotherapy With Nivolumab in Combination With Lenvatinib for Advanced Stage Hepatocellular Carcinoma | NCT03841201 | Advanced Hepato... | Lenvatinib Nivolumab | 18 Years - | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | |
| A Study of TAC-101 in Combination With TACE Versus TACE Alone in Asian Patients With Advanced Hepatocellular Carcinoma | NCT00756782 | Advanced Hepato... | TAC-101 Placebo | 18 Years - | Taiho Oncology, Inc. | |
| A Study Investigating the Efficacy and Safety of Ociperlimab and Tislelizumab and BAT1706 Combinations in Patients With Advanced HCC | NCT04948697 | Advanced Hepato... | Ociperlimab Tislelizumab BAT1706 | 18 Years - | BeiGene | |
| Study of Apatinib Combined With TACE in Advance Hepatocellular Carcinoma | NCT03398122 | Hepatocellular ... | TACE Apatinib | 18 Years - 70 Years | Tianjin Medical University Cancer Institute and Hospital | |
| Serplulimab Combined With Bevacizumab Biosimilar and HAIC in Advanced Hepatocellular Carcinoma (HCC) Patients | NCT06370065 | Advanced Hepato... | HAIC+Serplulima... | 18 Years - 75 Years | Tianjin Medical University Cancer Institute and Hospital | |
| Study of SHR-8068 Combined With Adebrelimab and Bevacizumab in the Treatment of Advanced Hepatocellular Carcinoma | NCT05444088 | Advanced Hepato... | Adebrelimab Bevacizumab SHR-8068 | 18 Years - 75 Years | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | |
| Concurrent Nivolumab and External Beam Radiation Therapy for Patients With Advanced HCC | NCT04611165 | Advanced Hepato... | Nivolumab | 20 Years - | National Cancer Center, Korea | |
| Rituximab Combined With Prior Therapy in Advanced Hepatocellular Carcinoma: Efficacy & Safety Study | NCT06301399 | Advanced Hepato... | Rituximab+PD-1 ... | 17 Years - 79 Years | Tianjin Medical University Cancer Institute and Hospital | |
| 68Ga PSMA PET Imaging for the Treatment of Advanced Liver Cancer | NCT05176223 | Advanced Hepato... Stage III Hepat... Stage IV Hepato... Unresectable He... | Computed Tomogr... Gallium Ga 68 G... Positron Emissi... | 18 Years - | Mayo Clinic | |
| A Study to Evaluate the Safety and Efficacy of PLM60 in Advanced HCC | NCT04331743 | Advanced Hepato... | Liposome-entrap... | 18 Years - 70 Years | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | |
| A Study of Tegavivint (BC2059) in Patients With Advanced Hepatocellular Carcinoma | NCT05797805 | Advanced Hepato... | Tegavivint Pembrolizumab | 18 Years - | Iterion Therapeutics | |
| A Study of SOT101 in Combination With Pembrolizumab to Evaluate the Efficacy and Safety in Patients With Selected Advanced Solid Tumors | NCT05256381 | Non-Small Cell ... Colorectal Canc... Cutaneous Squam... Hepatocellular ... Castration-resi... Ovarian Cancer | Nanrilkefusp Al... Pembrolizumab | 18 Years - | Sotio Biotech Inc. | |
| A Clinical Study of TQB2618 Injection Combined With Penpulimab Injection and Anlotinib Hydrochloride Capsules for First-line Treatment of Advanced Hepatocellular Carcinoma (HCC). | NCT05975645 | Advanced Hepato... | Penpulimab inje... TQB2618 injecti... Anlotinib Hydro... | 18 Years - 75 Years | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | |
| Single-arm, Open-label Clinical Study of SZ003 in the Treatment of Advanced Hepatocellular Carcinoma | NCT05845502 | Advanced Hepato... | SZ003 CAR-NK | 18 Years - 80 Years | Shantou University Medical College | |
| GH, IGF-I and Somatostatin Analogues in Hepatocellular Carcinoma | NCT00495846 | Advanced Hepato... | Octreotide-LAR,... Locoregional tr... | 18 Years - 75 Years | Federico II University | |
| A Study of Tegavivint (BC2059) in Patients With Advanced Hepatocellular Carcinoma | NCT05797805 | Advanced Hepato... | Tegavivint Pembrolizumab | 18 Years - | Iterion Therapeutics | |
| Itacitinib in Advanced Hepatocellular Carcinoma | NCT04358185 | Advanced Hepato... | Itacitinib (INC... | 18 Years - | Imperial College London | |
| A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With FOLFOX4 in Subjects With Advanced HCC Who Have Never Received Prior Systemic Treatment. | NCT03605706 | Advanced Hepato... | SHR-1210 FOLFOX4 Placebo | 18 Years - | Jiangsu HengRui Medicine Co., Ltd. | |
| A Study of CD147-targeted CAR-T by Hepatic Artery Infusions for Very Advanced Hepatocellular Carcinoma | NCT03993743 | Advanced Hepato... | CD147-CART | 18 Years - 65 Years | Xijing Hospital | |
| Phase I Clinical Trial of CT0181 Cells in the Treatment of Hepatocellular Carcinoma | NCT04973098 | Advanced Hepato... | CT0181 Cells | 18 Years - 75 Years | Peking University | |
| Anlotinib Hydrochloride Combined With Sintilimab Injection in the Treatment of Advanced Hepatocellular Carcinoma (HCC) | NCT04052152 | Advanced Hepato... | Anlotinib and S... | 18 Years - 70 Years | The First Affiliated Hospital with Nanjing Medical University | |
| A Study Investigating the Efficacy and Safety of Ociperlimab and Tislelizumab and BAT1706 Combinations in Patients With Advanced HCC | NCT04948697 | Advanced Hepato... | Ociperlimab Tislelizumab BAT1706 | 18 Years - | BeiGene | |
| A Study Evaluating the Efficacy and Safety of ZG005 in Combination With Donafenib or Bevacizumab in Patients With Advanced Hepatocellular Carcinoma | NCT06233994 | Advanced Hepato... | ZG005 Powder fo... Donafenib Tosil... Bevacizumab | 18 Years - | Changsha Taihe Hospital | |
| Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Participants With Advanced Hepatocellular Carcinoma | NCT02834780 | Advanced Hepato... Hepatocellular ... Liver Cancer Liver Neoplasms Hepatic Cancer Hepatic Carcino... | H3B-6527 | 18 Years - | Eisai Inc. | |
| AU409 for the Treatment of Advanced Primary Liver Cancers or Solid Tumor With Liver Metastatic Disease | NCT05791448 | Advanced Cholan... Advanced Hepato... Advanced Malign... Metastatic Mali... Refractory Mali... Stage III Hepat... Stage IV Hepato... | Biospecimen Col... Computed Tomogr... Magnetic Resona... RNA Transcripti... | 18 Years - | University of Southern California | |
| 4th Generation Chimeric Antigen Receptor T Cells Targeting Glypican-3 | NCT03980288 | Advanced Hepato... | CAR-GPC3 T Cell... | 18 Years - 75 Years | Zhejiang University | |
| Study of AU409 Capsule in Advanced Hepatocellular Carcinoma Patients Who Failed Standard Treatment | NCT06374485 | Advanced Hepato... | AU409 capsules | 18 Years - 75 Years | Lee's Pharmaceutical Limited | |
| IMC001 for Clinical Research on Advanced Digestive System Malignancies | NCT05028933 | Advanced Hepato... Advanced Colore... Advanced Gastri... Advanced Pancre... | EPCAM CAR-T | 18 Years - 70 Years | Zhejiang University | |
| A Study of TAE+HAIC Combined With Camrelizumab and Apatinib in the Treatment of Advanced Hepatocellular Carcinoma | NCT06363825 | Advanced Hepato... | camrelizumab | 18 Years - 80 Years | Fujian Medical University | |
| A Clinical Trial Evaluating the Safety and Efficacy of Intravenous CD-801 in Treating Advanced HCC Patients | NCT06418659 | Advanced Hepato... | CD-801 | 18 Years - | Shanghai Changzheng Hospital | |
| Immunotherapy Using Precision T Cells Specific to Multiple Common Tumor-Associated Antigen Combined With Transcatheter Arterial Chemoembolization for the Treatment of Advanced Hepatocellular Carcinoma | NCT02638857 | Recurrence Hepa... Advanced Hepato... | TACE Dendritic Cell lipiodol Mitomycin (MMC) Epirubicin(EADM... Precision Multi... | 18 Years - 65 Years | Second Military Medical University |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
